Common Warts Market Forecast Signals Robust Industry Growth Through 2036 - DelveInsight

DelveInsight's "Common Warts Market Insights, Epidemiology, and Market Forecast-2036′′ report offers an in-depth understanding of the Common Warts, historical and forecasted epidemiology as well as the Common Warts market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

Get a Free sample for the Common Warts Market Report:
https://www.delveinsight.com/report-store/common-warts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Some of the key facts of the Common Warts Market Report:
• The Common Warts market size was valued at approximately USD 1.0 billion in 2025 and is anticipated to witness substantial growth during the forecast period from 2026 to 2036, driven by increasing disease prevalence, growing treatment awareness, and advancements in dermatological therapies.
• In August 2026, Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a company focused on developing and commercializing therapies for dermatological conditions, including skin cancers, announced the completion of a credit facility of up to $27.5 million with an entity controlled by Paul B. Manning, the company's largest shareholder. The non-dilutive financing is expected to strengthen Verrica's financial resources, support the continued expansion of its YCANTH® business, and advance the company's global Phase III clinical program evaluating YCANTH for the treatment of common warts.
• In January 2026, Verrica Pharmaceuticals Inc. recently announced the launch of a global Phase III clinical development program to evaluate VP-102 for the treatment of common warts, with the first patient dosed in December 2025. This milestone marks an expansion of VP-102's clinical development beyond its approved use in molluscm contagiosum and underscores the company's continued commitment to addressing unmet needs in dermatology.
• In July 2025, Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a dermatology-focused therapeutics company specializing in treatments for skin conditions requiring medical intervention, announced it has signed a second amendment to its Collaboration and Licensing Agreement with Torii Pharmaceutical Co. Ltd. ("Torii"). This amendment supports the launch of a global pivotal Phase 3 clinical trial for Verrica's product, YCANTH®, aimed at treating common warts.
• In February 2025, Nielsen BioSciences, Inc., a privately held biopharmaceutical company based in San Diego, announced the successful enrollment of the final participant in CFW-3A-a Phase 3, randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of CANDIN® (Candida albicans Skin Test Antigen for Cellular Hypersensitivity) for treating common warts (Verruca vulgaris) in both adolescents and adults. CANDIN is not yet approved for this indication.
• According to DelveInsight's estimates, in 2025, the total number of prevalent cases of common warts in the 7MM were ~15,063,000.
• The highest burden is observed in children and adolescents, while immunocompromised individuals also show significantly increased incidence and persistence rates.
• HPV infections causing cutaneous warts are most commonly linked to low-risk types 1, 2, 4, 27, and 57, which account for the majority of common wart cases.
• In Europe, warts were identified as the most common skin disease, with a prevalence of 41.3%, highlighting their significant burden on dermatological health in the region.
• Plantar warts account for a significant proportion of cases in clinical settings, as they are more likely to become symptomatic due to pressure and pain on weight-bearing surfaces.
• Despite being benign, common warts show a high spontaneous resolution rate (within 1-2 years in many cases), but a substantial proportion persist or recur due to immune evasion by HPV.
• As per the secondary analysis, warts are a common condition worldwide, affecting about 10% of the population, with prevalence rising to 10-20% in school-aged children; they are rare in infancy and early childhood, increase during school years, peak between 12 and 16 years, and are more frequently observed in immunosuppressed individuals and meat handlers.
• Key Common Warts Companies: Nielsen BioSciences, Verrica Pharmaceutical, Kino Pharma/ Iwaki Pharmaceutical, Aclaris Therapeutics, Inc., KinoPharma Inc., ViroXis Corporation, Maruho Co., Ltd., Veradermics, Inc., Graceway Pharmaceuticals, LLC, MEDA Pharma, LEO Pharma, and others
• Key Common Warts Therapies: CANDIN, VP-102, FIT039, A-101, KNP2002, 10% EISO, CLS006, VDMN-21, Resiquimod, Imiquimod, Picato, and others
• The Common Warts epidemiology based on gender analyzed that the diagnosed prevalent cases were observed to be same for male and female in the 7MM
• The Common Warts market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Common Warts pipeline products will significantly revolutionize the Common Warts market dynamics.

Common Warts Overview
Common warts are benign growths on the skin caused by an infection with human papillomavirus (HPV). They are typically rough, raised, and have a grainy appearance. Common warts are most frequently found on the hands, fingers, and around the nails, but they can appear on other areas of the body as well.

To Know in detail about the Common Warts market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Common Warts Market Forecast
https://www.delveinsight.com/sample-request/common-warts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Common Warts Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Common Warts Epidemiology Segmentation:
The Common Warts market report proffers epidemiological analysis for the study period 2022-2036 in the 7MM segmented into:
• Total Prevalent Cases of Warts
• Total Diagnosed Prevalent Cases of Warts
• Total Diagnosed Prevalent Cases of Common Warts
• Treated Cases of Common Warts

Download the report to understand which factors are driving Common Warts epidemiology trends @ Common Warts Epidemiology Forecast
https://www.delveinsight.com/sample-request/common-warts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Common Warts Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Common Warts market or expected to get launched during the study period. The analysis covers Common Warts market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Common Warts Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Common Warts Therapies and Key Companies
• CANDIN: Nielsen BioSciences/Maruho
• VP-102: Verrica Pharmaceutical
• FIT039: Kino Pharma/ Iwaki Pharmaceutical
• A-101: Aclaris Therapeutics, Inc.
• KNP2002: KinoPharma Inc.
• 10% EISO: ViroXis Corporation
• CLS006: Maruho Co., Ltd.
• VDMN-21: Veradermics, Inc.
• Resiquimod: Graceway Pharmaceuticals, LLC
• Imiquimod: MEDA Pharma
• Picato: LEO Pharma

Discover more about therapies set to grab major Common Warts market share @ Common Warts Treatment Market
https://www.delveinsight.com/sample-request/common-warts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Common Warts Market Drivers
• High Prevalence of Human Papillomavirus (HPV) Infections: Common warts are caused by HPV, and the widespread prevalence of the virus continues to drive demand for effective treatment options.
• Growing Awareness of Skin Health: Increased awareness regarding dermatological conditions and the availability of treatment options is encouraging more patients to seek medical care.
• Advancements in Wart Treatment Technologies: The development of novel topical therapies, immunotherapies, laser treatments, and cryotherapy devices is improving treatment outcomes.
• Rising Demand for Minimally Invasive Procedures: Patients are increasingly opting for non-surgical and minimally invasive wart removal techniques due to their convenience and effectiveness.

Common Warts Market Barriers
• High Rate of Spontaneous Resolution: Many common warts resolve naturally without treatment, which can reduce the demand for medical intervention.
• Recurrence After Treatment: Warts may reappear even after successful treatment, posing challenges for long-term disease management.
• Availability of Over-the-Counter (OTC) Products: Widely available OTC treatments may limit the uptake of prescription therapies and clinical procedures.
• Limited Awareness in Certain Regions: Lack of awareness regarding available treatment options can result in delayed care-seeking behavior.

Scope of the Common Warts Market Report
• Study Period: 2022-2036
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Common Warts Companies: Nielsen BioSciences, Verrica Pharmaceutical, Kino Pharma/ Iwaki Pharmaceutical, Aclaris Therapeutics, Inc., KinoPharma Inc., ViroXis Corporation, Maruho Co., Ltd., Veradermics, Inc., Graceway Pharmaceuticals, LLC, MEDA Pharma, LEO Pharma, and others
• Key Common Warts Therapies: CANDIN, VP-102, FIT039, A-101, KNP2002, 10% EISO, CLS006, VDMN-21, Resiquimod, Imiquimod, Picato, and others
• Common Warts Therapeutic Assessment: Common Warts current marketed and Common Warts emerging therapies
• Common Warts Market Dynamics: Common Warts market drivers and Common Warts market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Common Warts Unmet Needs, KOL's views, Analyst's views, Common Warts Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.